SEC Form 4
Pharvaris N.V. (PHVS) insider trading
In the 12 months to Oct 26, 2026, 11 PHVS insiders reported open-market sales of $32.4M across 41 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $32.4M
- 41 filings · 11 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 28 of 41
- $15.3M of $32.4M sold (47%)
Who traded PHVS, and when
- Sale
- Sale, pre-arranged (10b5-1)
PHVS daily close from Oct 27, 2025 to Oct 26, 2026, between $21.59 and $38.86, last $31.76. 41 sale and 0 purchase filings by 11 insiders, marked at their filing dates. Schikan Johannes Gerardus Christiaan Petrus, Director: sold $9.7M across 6 filings, first filed Apr 24, 2026, last Sep 24, 2026. Peng Lu, Chief Medical Officer → President: sold $6.9M across 8 filings, first filed Apr 24, 2026, last Sep 21, 2026. Anne Lesage, Chief Early Development: sold $6.7M across 6 filings, first filed Apr 24, 2026, last Sep 21, 2026. Elisabeth Bjork, Director: sold $2.3M across 2 filings, first filed May 22, 2026, last Sep 21, 2026. Stefan Andreas Abele, Chief Technical Ops Officer: sold $2.0M across 2 filings, first filed May 19, 2026, last Sep 17, 2026. Robert Glassman, Director: sold $1.5M across 4 filings, first filed May 19, 2026, last Sep 21, 2026. 5 others: sold $3.3M across 13 filings, first filed Apr 10, 2026, last Sep 25, 2026.
Largest mark · tap a row for others
Schikan Johannes Gerardus Christiaan Petrus · Director
Filing 1 of 2 within a week · $7,028,952 total
Sale $7,000,000
200,000 shares at $35.00 avg
Filed Sep 21, 2026 · traded Sep 17
Close on filing date $36.02
Schikan Johannes Gerardus Christiaan Petrus · Director
Director
$9.7M soldPeng Lu · Chief Medical Officer → President
Chief Medical Officer → President
$6.9M soldAnne Lesage · Chief Early Development
Chief Early Development
$6.7M soldElisabeth Bjork · Director
Director
$2.3M soldStefan Andreas Abele · Chief Technical Ops Officer
Chief Technical Ops Officer
$2.0M soldRobert Glassman · Director
Director
$1.5M sold5 others
Combined, one mark per week
$3.3M soldOpen-market trades
41 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Schikan Johannes Gerardus Christiaan Petrus | Director | $9.7M | — | 6 | 27% of sales | |
| Peng Lu | Chief Medical Officer → President | $6.9M | — | 8 | 50% of sales | |
| Anne Lesage | Chief Early Development | $6.7M | — | 6 | 89% of sales | |
| Elisabeth Bjork | Director | $2.3M | — | 2 | 13% of sales | |
| Stefan Andreas Abele | Chief Technical Ops Officer | $2.0M | — | 2 | — | |
| Robert Glassman | Director | $1.5M | — | 4 | 42% of sales | |
| Wim Souverijns | Chief Commercial Officer | $1.3M | — | 2 | 100% of sales | |
| Berndt Modig | Chief Executive Officer | $1.1M | — | 7 | 100% of sales | |
| Viviane Monges | Director | $395.5K | — | 1 | — | |
| Anna Nijdam | Principal Accounting Officer | $307.5K | — | 2 | — | |
| David W. Nassif | CFO / CLO | $218.8K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Viviane Monges Director | Sale | 11,969 | $33.05 | $395.5K | 5,500 | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 800 | $36.19 | $29.0K | 115,167 | |
traded | David W. Nassif CFO / CLO | Sale | 6,000 | $36.47 | $218.8K | 114,300 | |
traded | Anne Lesage Chief Early Development | Sale | 20,000 | $38.27 | $765.5K | 73,969 | |
traded | Robert Glassman Director | Sale | 14,493 | $38.56 | $558.8K | 10,500 | |
traded | Elisabeth Bjork Director | Sale | 52,500 | $37.89 | $2.0M | 15,167 | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 200,000 | $35.00 | $7.0M | 115,167 | |
traded | Peng Lu President | Sale | 100,000 | $35.00 | $3.5M | 64,953 | |
traded | Robert Glassman Director | SalePre-arranged (10b5-1) | 8,667 | $38.27 | $331.7K | 10,500 | |
traded | Stefan Andreas Abele Chief Technical Ops Officer | Sale | 46,400 | $38.17 | $1.8M | 40,468 | |
traded | Wim Souverijns Chief Commercial Officer | SalePre-arranged (10b5-1) | 26,090 | $39.23 | $1.0M | 39,021 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,291 | $39.40 | $90.3K | 128,334 | |
traded | Peng Lu President | SalePre-arranged (10b5-1) | 15,000 | $40.13 | $601.9K | 65,179 | |
traded | Anne Lesage Chief Early Development | SalePre-arranged (10b5-1) | 30,000 | $38.30 | $1.1M | 56,450 | |
traded | Robert Glassman Director | SalePre-arranged (10b5-1) | 8,000 | $37.55 | $300.4K | 10,500 | |
traded | Peng Lu President | SalePre-arranged (10b5-1) | 15,000 | $40.68 | $610.1K | 65,179 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,292 | $34.77 | $79.7K | 130,625 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,292 | $34.97 | $80.2K | 132,917 | |
traded | Anne Lesage Chief Early Development | SalePre-arranged (10b5-1) | 76,172 | $35.39 | $2.7M | Multiple accounts | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | SalePre-arranged (10b5-1) | 37,600 | $35.41 | $1.3M | 315,167 | |
traded | Peng Lu Chief Medical Officer | SalePre-arranged (10b5-1) | 29,700 | $34.30 | $1.0M | 65,631 | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | SalePre-arranged (10b5-1) | 2,400 | $35.10 | $84.2K | 352,767 | |
traded | Anne Lesage Chief Early Development | SalePre-arranged (10b5-1) | 4,600 | $35.12 | $161.6K | Multiple accounts | |
traded | Peng Lu Chief Medical Officer | SalePre-arranged (10b5-1) | 300 | $34.00 | $10.2K | 65,631 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,291 | $31.07 | $71.2K | 135,209 | |
traded | Anna Nijdam Principal Accounting Officer | Sale | 2,670 | $30.87 | $82.4K | 46,275 | |
traded | Anna Nijdam Principal Accounting Officer | Sale | 7,330 | $30.70 | $225.1K | 48,945 | |
traded | Elisabeth Bjork Director | SalePre-arranged (10b5-1) | 10,000 | $29.32 | $293.2K | 15,167 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,292 | $29.22 | $67.0K | 137,500 | |
traded | Wim Souverijns Chief Commercial Officer | SalePre-arranged (10b5-1) | 10,000 | $29.92 | $299.2K | 45,111 | |
traded | Stefan Andreas Abele Chief Technical Ops Officer | Sale | 8,748 | $29.82 | $260.9K | 35,194 | |
traded | Robert Glassman Director | Sale | 10,000 | $29.82 | $298.2K | 15,167 | |
traded | Peng Lu Chief Medical Officer | SalePre-arranged (10b5-1) | 14,166 | $30.17 | $427.4K | 66,226 | |
traded | Peng Lu Chief Medical Officer | SalePre-arranged (10b5-1) | 18,733 | $30.21 | $565.9K | 66,083 | |
traded | Anne Lesage Chief Early Development | SalePre-arranged (10b5-1) | 48,300 | $30.23 | $1.5M | Multiple accounts | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | SalePre-arranged (10b5-1) | 32,900 | $30.29 | $996.5K | 355,837 | |
traded | Peng Lu Chief Medical Officer | SalePre-arranged (10b5-1) | 7,101 | $30.05 | $213.4K | 66,083 | |
traded | Anne Lesage Chief Early Development | SalePre-arranged (10b5-1) | 14,700 | $30.05 | $441.7K | Multiple accounts | |
traded | Schikan Johannes Gerardus Christiaan Petrus Director | SalePre-arranged (10b5-1) | 7,100 | $30.05 | $213.4K | 388,067 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 2,292 | $28.60 | $65.6K | 139,792 | |
traded | Berndt Modig Chief Executive Officer | SalePre-arranged (10b5-1) | 23,333 | $27.74 | $647.3K | 142,084 |
GET /stocks/filings/vX/form-4?tickers=PHVS&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PHVS"
],
"issuer_cik": "0001830487",
"owner_cik": "0001838204",
"accession_number": "0001193125-26-402567",
"form_type": "4",
"filing_date": "2026-09-25",
"period_of_report": "2026-09-23",
"issuer_name": "Pharvaris N.V.",
"issuer_trading_symbol": "PHVS",
"owner_name": "Monges Viviane",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-23",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 11969,
"transaction_price_per_share": 33.0457,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 5500,
"transaction_value": 395523.98329999996,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."
}
]
},
{
"tickers": [
"PHVS"
],
"issuer_cik": "0001830487",
"owner_cik": "0002014983",
"accession_number": "0001193125-26-400435",
"form_type": "4",
"filing_date": "2026-09-24",
"period_of_report": "2026-09-22",
"issuer_name": "Pharvaris N.V.",
"issuer_trading_symbol": "PHVS",
"owner_name": "Schikan Johannes Gerardus Christiaan Petrus",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-22",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 800,
"transaction_price_per_share": 36.19,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 115167,
"transaction_value": 28952,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $36.15 to $36.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 60 records
- Option exercises41 records
- Tax withholding16 records
- Tax withholding (sold to cover)2 records
- Gifts1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Pharvaris N.V.'s CEO sold stock?
Yes. Berndt Modig (CEO) sold 37,083 shares ($1.1M) between Apr 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is PHVS’s insider data?
These are PHVS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PHVS insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PHVS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.